aspergillosis
ASPERGILLOSIS
Aspergillosis encompasses a variety of clinical syndromes depending on host immunity factors.
It is caused by Aspergillus, an ubiquitous, soil-dwelling, filamentous fungus that grows on soil, food, dead leaves, household dust, etc. It grows best at 37ºC and the small spores are easily inhaled and deposited deep in the lungs.
The most common pathogens are Aspergillus fumigatus, A. flavus, A. niger and A. terreus.
Aspergilloma is a conglomeration of intertwined Aspergillus hyphae, fibrin, mucus and cellular debris within a pulmonary cavity or an ectatic bronchus.

Surgical Intervention

  • Surgical resection is the definitive treatment for single pulmonary aspergillomas and Aspergillus fungal ball of the paranasal sinus
  • Surgical excision has an important role in the invasion of bone, burn wounds, epidural abscesses and vitreal disease
    • May also be valuable when invasive pulmonary disease fails aggressive antifungal chemotherapy
  • Surgical resection of Aspergillus-infected tissue may be useful in patients with lesions that are near the great vessels or pericardium, lesions causing hemoptysis or uncontrolled bleeding from a single focus, and lesions causing erosion into the pleural space or ribs
  • Localized disease may benefit from debridement (eg sinus aspergillosis, cutaneous aspergillosis) 
  • Should also be considered in Aspergillus osteomyelitis, central nervous system aspergillosis, pericardial infection and endocarditis
  • Another relative indication is the resection of a single pulmonary lesion prior to intensive chemotherapy or hematopoietic stem cell transplantation (HSCT)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
15 Aug 2017
New drug applications approved by US FDA as of 1 - 15 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
04 Aug 2017
Chronic obstructive pulmonary disease (COPD) is the fourth cause of global mortality, with experts predicting a potential future rise in the prevalence rates of COPD. 
11 May 2016

In conjunction with World Asthma Day which falls on 3rd May 2016, MIMS Doctor speaks to a renowned respiratory medicine specialist, Dato' Dr. Hj Abdul Razak Abdul Muttalif, regarding the chronic airway disease.

Pearl Toh, 22 May 2016
Asthma patients on salmeterol, a long-acting beta-agonist (LABA), plus fluticasone inhaled corticosteroid (ICS) combination therapy did not have a greater risk of serious asthma-related events compared with patients receiving fluticasone alone, according to the recent AUSTRI* study.